Affiliation:
1. Department of Energy and Biotechnology, Graduate School, Dongseo University, Busan 47011, Republic of Korea
2. Drug Information Platform Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea
3. Department of Bio-Pharmaceutical Engineering, College of Bio-Health Convergence, Dongseo University, Busan 47011, Republic of Korea
Abstract
Atopic dermatitis (AD) is a common inflammatory skin disease characterized by pruritic lesions and skin barrier dysfunction. In this study, we evaluated the effect of a quinazoline derivative, SH-340, on TSLP expression and signaling in human primary keratinocytes. Our results demonstrated that SH-340 significantly increased factors for differentiation and skin barrier function including KRT1, KRT2, KRT10, IVL, LOR, CLDN1, OVOL1, and FLG, whereas it inhibited TSLP expression in a dose-dependent manner, both at the mRNA and protein levels. Furthermore, SH-340 was found to inhibit the phosphorylation of STAT6, a downstream signaling molecule of IL-4 and IL-13, in keratinocytes. These findings suggest that SH-340 may suppress TSLP expression by inhibiting the IL-4/IL-13-STAT6 signaling pathway. Finally, SH-340 may potentially contribute to both the alleviation of inflammation and the restoration of skin barrier function.
Funder
National Research Foundation of Korea
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference32 articles.
1. Alsibaee, A.M., Al-Yousef, H.M., and Al-Salem, H.S. (2023). Quinazolinones, the winning horse in drug discovery. Molecules, 28.
2. The antibacterial activity of quinazoline and quinazolinone hybrids;Li;Curr. Top. Med. Chem.,2022
3. Discovery of quinazolin-4(3h)-one derivatives as novel ache inhibitors with anti-inflammatory activities;Lv;Eur. J. Med. Chem.,2023
4. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors;Powell;Br. J. Dermatol.,1999
5. Structure–activity relationship for the 4(3h)-quinazolinone antibacterials;Bouley;J. Med. Chem.,2016